MSMelek Sezgin

Melek Sezgin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Melek Sezgin has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association of rs2252070 MMP13 polymorphism with unilateral cerebral palsy in Turkish children

    by Orhan Güvener, İbRahim Ömer Barlas, Melek Sezgin, Özlem Tezol, Asena Ayça Özdemir

    Purpose: Cerebral Palsy (CP) is a group of movement and posture disorders whose etiology is heterogeneous and multifactorial. Evidence suggests that genetic factors may be responsible for the etiology of CP. This study aimed to investigate the potential genetic underpinnings of CP by examining the association between the MMP13 rs2252070 polymorphism and CP.Materials and Methods: This cross-sectional case-control study included 41 children with CP (19 males, 22 females) and 41 healthy children (16 males, 25 females). Genomic DNA extracted from peripheral blood samples was genotyped using specific primers and probes targeting the relevant polymorphic sequence. Genotype distributions and allele frequencies were compared between the patient and control groups. Furthermore, subgroup analyses were conducted based on the clinical characteristics of patients with CP. Results: The genotype distributions of the groups were in Hardy-Weinberg equilibrium. No significant differences were observed in the MMP13 rs2252070 genotype and allele distributions between the age- and gender-matched groups (genotype frequencies in the CP group: CC 17.1%, CT 41.5%, TT 41.5%; controls: CC 17.1%, CT 31.7%, TT 51.2%; allele frequencies in the CP group: C 37.8%, T 62.2%; controls: C 32.9%, T 67.1%).Conclusion: These findings suggest that the MMP13 rs2252070 genetic polymorphism is not significantly associated with CP susceptibility in the Turkish population and does not play a role in the pathogenesis of CP.

  • Psychometric properties of the MOS sleep scale in Turkish patients with knee osteoarthritis: A methodological validation study

    by Melek Sezgin, Evren Yeşildal, Pınar Müge Sarıkaya, Handan Ankaralı, Günşah Sahin

    Objective: To investigate if the Medical Outcomes Study (MOS) sleep scale was reliable, valid, and responsiveness to treatment in Turkish patients with knee osteoarthritis (OA). Patients and Methods: This is a methodological validation study. One hundred patients with knee OA and 75 healthy controls were included. The MOS sleep scale was administered to two groups to assess sleep status. The reliability of the questionnaire was assessed using reproducibility and internal consistency (Cronbach's alpha and item-total correlation). To assess reproducibility, the questionnaire was administered twice at 3-day intervals before treatment. It was also administered to patients at the end of treatment to investigate responsiveness to treatment. To assess concurrent validity, correlations with the NHP (Nottingham Health Profile) and the WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) were examined. Results: The MOS sleep scale all scores were significantly lower in patients with knee OA than in controls (p < 0.05). After the treatment, a significant improvement was observed in all MOS sleep scale scores of the patients (p < 0.05). The Turkish version of the MOS sleep scale was reliable with strong internal consistency (Cronbach alpha: 0.74–0.85 and Item-total correlation:0.50–0.89) and good reproducibility (intra-reader correlation:0.47–0.83, inter-reader correlation:0.43–0.84) in patients with knee OA. When assessing concurrent validity of the scale, it was determined that its correlations with WOMAC and NHP scores were moderate and good levels (r = −0.21–0.50, p = 0.03–0.0001). Conclusion: Our study showed that the MOS sleep questionnaire is a valid, reliable, and treatment-responsive scale in Turkish patients with knee OA.

  • Open Access

    Validation of the Pediatric Quality of Life Inventory 3.0 Cerebral Palsy Module (Parent Form) for use in Türkiye

    by Sehim Kutlay, Birkan Sonel Tur, Melek Sezgin, Atilla Halil Elhan, Derya Gökmen, Alan Tennant, Ayşe Adile Küçükdeveci

    Objectives: This study was planned to test the reliability and validity of the Turkish version of the Pediatric Quality of Life Inventory (PedsQL) 3.0 cerebral palsy (CP) module (parent form) in children with CP. Patients and methods: In the validation study conducted between June 2007 and June 2009, 511 children (299 normal children, 212 children with CP) were assessed by the seven scales of PedsQL [daily activities (DA), school activities (SA), movement and balance (MB), pain and hurt (PH), fatigue (F), eating activities (EA), and speech and communication (SC)]. Reliability was tested by internal consistency and person separation index (PSI); internal construct validity by Rasch analysis and external construct validity by correlation with the Gross Motor Function Classification System (GMFCS) and Functional Independence Measure for Children (WeeFIM). Results: Only 13 children with CP completed the inventory by themselves and thus were excluded. Consequently, 199 children with CP (113 males, 86 females; mean age: 7.3±4.2 years; range, 2 to 18 years) and 299 normal children (169 males, 130 females; mean age: 9.4±4.0 years; range, 2 to 17 years) were included in the final analysis. Reliabilities of the seven scales of the PedsQL 3.0 CP module were adequate, with Cronbach’s alphas between 0.66 and 0.96 and the PSI between 0.672 and 0.943 for the CP group. In Rasch analysis, for each scale, items showing disordered thresholds were rescored; then testlets were created to overcome local dependency. Internal construct validity of the unidimensional seven scales was good with the mean item fit of -0.107±1.149, 0.119±0.818, 0.232±1.069, -0.442±0.672, 0.221±0.554, -0.091±0.606, and -0.333±1.476 for DA, SA, MB, PH, F, EA, and SC, respectively. There was no differential item functioning. External construct validity of the instrument was confirmed by expected moderate to high correlations with WeeFIM and GMFCS (Spearman’s r=0.35-0.89). Conclusion: Turkish version of the PedsQL 3.0 CP module is reliable, valid, and available for use in clinical setting to evaluate health-related quality of life of children with CP.


  • Open Access

    Are COL4A1 and COL4A2 gene polymorphisms associated with cerebral palsy?

    by Orhan Güvener, Melek Sezgin, Özlem Tezol, İbRahim Ömer Barlas, Asena Ayça Özdemir, Emine Arzu Kanık

    Objectives: This study aims to investigate the association of COL4A1 and COL4A2 gene polymorphisms with susceptibility to risk of developing cerebral palsy (CP) and severity of CP. Patients and methods: Between December 2016 and June 2017, a total of 176 patients with CP (101 males, 75 females; mean age 71.8±37.9 months; range, 24 to 184 months) and age-, sex-, and ethnically-matched 178 (90 males, 88 females; mean age 69.3±55.2 months; range, 24 to 214 months) controls were included. Two polymorphisms of COL4A1 (rs1961495) and COL4A2 (rs9521733) genes were typed from genomic deoxyribonucleic acid. Genotype distributions and allelic frequencies were compared between the patient and control groups. Gross Motor Function Classification System, the use of medical drugs, type of involvement, number of affected limbs, accompanying conditions, birth weight, gestational age, and magnetic resonance imaging (MRI) findings were used to evaluate the disease severity and their relationships with the COL4A1 and COL4A2 gene polymorphisms. Results: There was no statistically significant difference between the groups in terms of genotype distribution and allele frequency of COL4A1 and COL4A2 gene polymorphisms (p>0.05). In addition, there was no relationship between severity of CP and two gene polymorphisms (p>0.05). A significant association was detected between the COL4A2 polymorphism and growth retardation in CP. The TT genotype (57.1%) and T allele (76.2%) were higher, compared to CC (4.8%) and CT genotypes (38.1%) and C allele (23.8%) in patients with CP with growth retardation (p=0.03 for genotype and p=0.01 for allele frequency). Conclusion: These findings suggest that COL4A1 and COL4A2 gene polymorphisms are not associated with susceptibility to CP in a group of Turkish populations, although COL4A2 gene polymorphism may be associated with growth retardation in patients with CP.


  • Open Access

    Consensus recommendations for botulinum toxin injections in the spasticity management of children with cerebral palsy during COVID-19 outbreak

    by Ebru Yilmaz Yalçinkaya, Evrim Karadağ Saygi, Özden Özyemi̇şçi̇ Taşkiran, Nalan Çapan, Şehim Kutlay, Birkan Sonel Tur, Özlem EL, Ece Ünlü Akyüz, Süda Teki̇n, Demet Ofluoğlu, et al.

    Spasticity is the most common motor disturbance in cerebral palsy (CP). Lockdown in the COVID-19 outbreak has profoundly changed daily routines, and similarly caused the suspension of spasticity treatment plans. Besides, the delay in botulinum toxin (BoNT) injection, which is important in the management of focal spasticity, led to some problems in children. This consensus report includes BoNT injection recommendations in the management of spasticity during the COVID-19 pandemic in children with CP. In order to develop the consensus report, physical medicine and rehabilitation (PMR) specialists experienced in the field of pediatric rehabilitation and BoNT injections were invited by Pediatric Rehabilitation Association. Items were prepared and adapted to the Delphi technique by PMR specialists. Then they were asked to the physicians experienced in BoNT injections (PMR specialist, pediatric orthopedists, and pediatric neurologists) or COVID-19 (pediatric infectious disease, adult infectious disease). In conclusion, the experts agree that conservative management approaches for spasticity may be the initial steps before BoNT injections. BoNT injections can be administered to children with CP with appropriate indications and with necessary precautions during the pandemic.